Floatz logo

mk-2206

Ovarian Sarcoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

1 Active assets in the Ovarian Sarcoma cohort.

Asset / SponsorPhaseRating
Ziv-Aflibercept
National Cancer Institute (NCI)
Phase 2B
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Angiotensin-(1-7)
Wake Forest University Health Sciences
Phase 2CCC
Gdc-0449
National Cancer Institute (NCI)
Phase 1/2CCC
Carboplatin
Case Comprehensive Cancer Center
Phase 1CCC

View all 14 →

Same molecule, other indications

mk-2206 is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
diffuse large B-cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
prostate cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →